LEUKOCARE and Boehringer Ingelheim enter into a long-term agreement in the field of animal health
The biotechnology company LEUKOCARE has established another important partnership by licensing its Stabilizing and Protecting Solutions (SPS(R)) technologies. According to the Munich-based company, LEUKOCARE has entered into a license agreement with Boehringer Ingelheim. On the basis of this agreement, the animal health business unit of the pharmaceutical company Boehringer Ingelheim will have access to LEUKOCARE's SPS(R) formulation technologies to utilize biological reagents in a new veterinary diagnostics product and to stabilize them. In this context, portable analytical devices support the veterinarian's decision making directly on site and in a minimum of time without shipment of samples. License and payment terms have not been disclosed by the partners.
Rolf-Dieter Günther, Head of Diagnostics at Boehringer Ingelheim, commented, "Thanks to LEUKOCARE's expertise and its SPS(R) technologies, we have been able to develop a new diagnostic concept in animal health. The diagnostics platform will enable veterinarians to get a quick, easy and safe test to be performed directly at the stable or at the pet owner's home."
Michael Scholl, CEO of LEUKOCARE, said, "After having already worked with Boehringer Ingelheim for a longer period of time and being closely involved in their development activities, we are delighted to support our partner with our SPS(R) technologies in this exciting application. This once again proves the high quality of our SPS(R) formulation technology platform, and, on the other hand, our outstanding development skills."
This is LEUKOCARE's third license agreement within 15 months. End of 2016, the company entered into a comparable license agreement with US-based vaccine company PaxVax and in February 2017, a strategic alliance with Laupheim-based Rentschler Biopharma SE was established. Scholl anticipates further agreements in the coming months.